Consensus of Experts Regarding the Clinical Utilization of Yishen Huashi Granules in Kidney Disease Management

Yishen Huashi Granules, initially known as “Mankidneyan,” represent a category six traditional Chinese medicine that was recently developed by Guangzhou Kangchen Pharmaceutical Co., Ltd. This medication received approval from the China Food and Drug Administration (CFDA) in March 2009. Its primary purpose is to address proteinuria, a common symptom associated with chronic glomerulonephritis characterized by a syndrome of spleen deficiency and dampness excess. This condition is typically diagnosed when serum creatinine levels (Scr) are less than 2 mg/dl. Patients with this condition often exhibit symptoms such as edema, fatigue, aversion to cold, cold limbs, and poor appetite. Over the past few years, Yishen Huashi Granules have garnered widespread recognition for their effectiveness in treating chronic kidney disease (CKD) as a result of accumulating clinical experience. However, there have also been instances of off-label use. In an effort to provide clear guidance and standardization for the clinical Utilization of Yishen Huashi Granules in CKD Management, the Chinese Association of Traditional Chinese Medicine has convened a panel of experts from various disciplines, including clinical nephrology, pharmacology, and statistics. These experts have been tasked with reviewing, summarizing, and analyzing research findings both before and after the medication’s approval for marketing. Leveraging the collective clinical experience of these experts, an “Expert Consensus on the Clinical Application of Yishen Huashi Granules in the Treatment of Kidney Diseases” has been developed. The primary objective of this consensus is to broaden the range of indications for the medication and enhance the existing application guidelines. Ultimately, this effort aims to promote the rational and well-informed clinical use of Yishen Huashi for of kidney illness.